

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Inventors: Slade et al.)	
)	
Application No.: 10/593,180)	
)	Group Art Unit: 1626
Filed: September 13, 2006)	
)	Examiner: Unknown
For: PHARMACEUTICAL)	
COMPOSITION AND METHOD)	
)	

**INFORMATION DISCLOSURE STATEMENT
UNDER 37 CFR § 1.97(b)(3)**

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Attached is a list of documents on form PTO/SB/08A. Copies of foreign patent documents and non-patent literature are enclosed pursuant to 37 C.F.R. § 1.98(a)(2). Pursuant to 1276 OG 55 dated August 5, 2003, copies of U.S. patents and U.S. publications are not being provided.

It is requested that the Examiner consider these documents and officially make them of record in accordance with the provisions of 37 CFR § 1.97 and Section 609 of the MPEP. By submitting the listed documents, Applicants are in no way making any admission as to prior art status of the listed documents, but are instead submitting the listed documents for the sake of full disclosure under 37 CFR § 1.56.

To the best of the undersigned person's knowledge, this Information Disclosure Statement is being submitted in accordance with 37 CFR § 1.97(b)(3), before the mailing of a first Office Action on merits.

It is believed that neither an extension of time, nor payment of any fee is required in connection with this communication. However, if an extension of time and corresponding extension fee, or any other fee is required, such an extension of time is hereby petitioned for and the Commissioner is authorized to charge any fees, or credit any overpayment, to Deposit Account No. **50-1627**.

Respectfully submitted,

/Jonathan A. Baker/

Jonathan A. Baker, Ph.D.
Registration No. 49,022

Intellectual Property Department
Myriad Genetics, Inc.
(Customer No. 26698)
320 Wakara Way
Salt Lake City, UT 84108
Telephone: 801-584-3600
Fax: 801-883-3871

Date: March 12, 2007